Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug, Other, Procedure
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Diagnosis of open-angle glaucoma or ocular hypertension in the study eye
Locations
United States
Colorado
Glaukos Investigative Site
RECRUITING
Grand Junction
Oklahoma
Glaukos Investigative Site
RECRUITING
Oklahoma City
Texas
Glaukos Clinical Site
RECRUITING
El Paso
Contact Information
Primary
Study Director
ClinicalResearch@glaukos.com
949-739-8749
Time Frame
Start Date: 2025-06-12
Estimated Completion Date: 2032-03
Participants
Target number of participants: 110
Treatments
Experimental: Period 1 (Cohort A)
Single-arm, open-label portion of Phase 2; subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and be followed for 36 months
Experimental: Period 2 (Cohort B) Gen 2 Travoprost Intracameral Implant Arm
Randomized, double-masked, active-controlled Phase 2 portion of the trial; subjects will receive second generation travoprost intracameral implant (plus placebo eyedrops BID) in the study eye and be followed for 36 months
Active_comparator: Period 2 (Cohort B) Timolol Arm
Randomized, double-masked, active-controlled, Phase 2 portion of the trial; subjects will administer timolol 0.5% eye drops BID (plus sham procedure) in the study eye and be followed for 36 months
Related Therapeutic Areas
Sponsors
Leads: Glaukos Corporation